Dr.TWL Dermaceuticals continues its trajectory as a leader in Asian biotechnology. With the establishment of the Asian Bio-Dermatology Institute in Guangdong, we are bridging international clinical standards with the tech dominance of the Greater Bay Area. Our latest patent-filing for Signature Purple Code™ marks a strategic milestone in our IP portfolio, merging emotion-responsive AI with industrial-scale pharmaceutical engineering. This expansion allows for unprecedented R&D into rare Eastern ethnobotanicals and climate-adaptive AI protocols.
Strategic Growth in the Greater Bay Area (GBA)
The announcement of the Signature Purple Code™ patent coincides with a massive expansion of our R&D footprint. By establishing the Asian Bio-Dermatology Institute in Guangdong, we are positioning Singaporean dermatological expertise at the heart of the world’s most advanced biotechnology hub.
The GBA Advantage
“The Greater Bay Area provides a mature infrastructure that allows us to scale our pharmaceutical engineering,” says Justin Teo, Lead Pharmaceutical Engineer. This partnership enables us to conduct rigorous clinical trials and industrial-scale extraction of rare ethnobotanicals, ensuring that our products meet the highest international medical standards while utilizing cutting-edge regional tech dominance.
Building a 2026 IP Portfolio
This launch is the latest in a series of strategic IP filings. Our 2026 patented Transdermal Hydrogel Interface represents a major leap in delivery systems, allowing for the integration of traditional Eastern medicine with modern clinical bio-actives.
The Roadmap for 2026 and Beyond
Climate-Adaptive AI Looking ahead, the roadmap for Signature Purple Code™ enters its most intuitive phase yet—incorporating research-backed skin microclimate analysis as well as user emotional data.By integrating live facial sentiment analysis, the system will soon be capable of reading subtle micro-expressions to sense a user’s emotional state in real-time. This allows the protocol to autonomously recalibrate, harmonizing clinical dermocosmetic interventions with both the internal mood and external environmental stressors. It is a milestone that underscores Dr.TWL’s role in defining the vanguard of the C-Beauty biotech movement.
FOR IMMEDIATE RELEASE
Dr.TWL Unveils the Beauty Industry’s First Psychodermatology Protocol, Merging Emotion-Responsive AI with C-Beauty Biotech
The Asian dermocosmetic pioneer introduces the AI Bio-Sommelier, a patent-pending closed-loop system bridging photobiomodulation, acoustic neuro-regulation and heritage ethnobotany.
[SINGAPORE, 2 APRIL 2026] – Asian dermocosmetic brand Dr. TWL Dermaceuticals today unveils Signature Purple Code™, a patent-pending psychodermatological protocol bridging emotion-responsive AI and photobiomodulation (PBM) therapy with TRPV-1 regulating neurocosmetics.
Dermatologist-developed to stabilize reactive skin for the modern urbanite, Signature Purple Code™ fuses mitochondrial ATP activation with neuro-acoustic regulation. By synchronizing quad-spectrum light wavelengths with targeted low-frequency acoustic resonances, the system facilitates a state of deep neurological rest. It is the industry’s first closed-loop psychodermatological protocol designed to neutralize the total skin exposome.
Rooted in Chief Scientific Officer Dr. Teo Wan Lin’s published research on microclimate-linked dysbiosis and the psychodermatological feedback loop in leading journals such as the Journal of the American Academy of Dermatology, the proprietary AI Bio-Sommelier interface regulates thermal and affective aging via TRPV1-sensory receptor targeting and ritual science.
Powered by a proprietary quad-spectrum engine, the light protocols activate the Bibang complex™—a TRPV1-modulating ethnobotanical quartet of Belamcanda, Hiba, Scutellaria, and Peony delivered in a cooling hydrogel matrix.
“There is a well-founded basis for the brain-skin-axis, both as a bidirectional ecosystem and as a dermatological principle that skin cells and the nervous system share an embryological origin,” says Dr. Teo Wan Lin. “Our goal is to materialize these protocols as cutting-edge dermocosmetic interventions, rooted in a blend of dermatological science, eastern ethnobotanical tradition, and heritage rituals.”
Riding the C-Beauty Biotech Wave
Founded in 2016, the brand has significantly expanded its R&D footprint beyond its manufacturing headquarters in Korea. Dr.TWL Dermaceuticals recently announced the establishment of the Asian Bio-Dermatology Institute in Guangdong, a dedicated biotechnology research arm focusing on the development of ethnobotanical-peptide neurocosmetics.
“The Asian Bio-Dermatology Institute is established in strategic partnership with a premier biotechnology player in Guangdong,” explains Justin Teo, the brand’s Lead Pharmaceutical Engineer. “This expansion grants us access to pharmaceutical engineering and clinical testing for rare ethnobotanicals. It allows us to conduct rigorous clinical trials on heritage ingredients such as Scutellaria Baicalensis and Paeonia Suffruticosa at an unprecedented scale.”
About Dr.TWL®
Dr.TWL Dermaceuticals is a dermatologist-developed Asian dermocosmetic brand established since 2016, bridging modern exposome science with traditional ethnopharmacology. Headquartered in Singapore with established R&D in Korea and China, the brand’s research arm holds a growing IP portfolio, including a 2026 patented Transdermal Hydrogel Interface incorporating fractionated TCM complexes with clinical bio-actives.
The brand’s flagship innovation, Signature Purple Code™, is a patent-pending integrated dermatological control system codifying emotion-responsive AI with advanced light synchronization, adaptive thermal interfaces, and high-performance matrix structures for psychodermatological interventions.
Co-developed by board-certified dermatologist Dr. Teo Wan Lin and pharmaceutical engineer Justin Teo Zhi Liang, the Bibang Protocol™ bypasses the 500 Dalton Rule through advanced bio-fermentation to ensure deep dermal delivery of high-molecular-weight actives.
Media Contact
Ms Joanne Lim
Dr.TWL Dermaceuticals
Email:
manager@twlskin.com